VIEKIRA XR Drug Patent Profile

Which patents cover Viekira Xr, and what generic alternatives are available?

Viekira Xr is a drug marketed by Abbvie and is included in one NDA. There are eighteen patents protecting this drug.

This drug has five hundred and fifty-two patent family members in fifty-two countries.

The generic ingredient in VIEKIRA XR is dasabuvir sodium; ombitasvir; paritaprevir; ritonavir. Additional details are available on the dasabuvir sodium; ombitasvir; paritaprevir; ritonavir profile page.

DrugPatentWatch^® Generic Entry Outlook for Viekira Xr

Viekira Xr was eligible for patent challenges on December 19, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 2, 2035. This may change due to patent challenges or generic licensing.

There have been seventeen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for VIEKIRA XR

International Patents:	552
US Patents:	18
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	3
Patent Applications:	84
Drug Prices:	Drug price information for VIEKIRA XR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIEKIRA XR
DailyMed Link:	VIEKIRA XR at DailyMed

See drug prices for VIEKIRA XR

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VIEKIRA XR

NDA:

208624

Dosage:

TABLET, EXTENDED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VIEKIRA XR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Massachusetts General Hospital	Phase 4
Merck Sharp & Dohme Corp.	Phase 4
University of Florida	Phase 4

See all VIEKIRA XR clinical trials

US Patents and Regulatory Information for VIEKIRA XR

VIEKIRA XR is protected by eighteen US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No			Y	Y
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No			Y	Y
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No			Y

Expired US Patents for VIEKIRA XR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016

International Patents for VIEKIRA XR

When does loss-of-exclusivity occur for VIEKIRA XR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

European Patent Office

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VIEKIRA XR around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2283844	Forme posologique pharmaceutique solide comprenant du lopinavir (A solid pharmaceutical dosage formulation comprising lopinavir)
Canada	2736895
Eurasian Patent Organization	201490837
South Africa	201507080	METHODS FOR TREATING HCV COMPRISING AT LEAST TWO DIRECT ACTING ANTIVIRAL AGENT, RIBAVIRIN BUT NOT INTERFERON
South Korea	20130053440	고체 조성물 (SOLID COMPOSITIONS)

Supplementary Protection Certificates for VIEKIRA XR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2340029	132016000021931	Italy		PRODUCT NAME: PARITAPREVIR IN TUTTE LE FORME PROTETTE DAL BREVETTO DI BASE(VIEKIRAX); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/982/001, 20150119
2692346	SPC/GB17/056	United Kingdom		PRODUCT NAME: PIBRENTASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/17/1213 (NI) 20170728; UK PLGB 41042/0030 20170728; UK PLGB 41042/0043 20170728
2368890	C02368890/01	Switzerland		FORMER OWNER: ABBVIE BAHAMAS LIMITED, BS
2340029	1590012-9	Sweden		PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REG. NO/DATE: EU/1/14/982 20150119
2692346	C201730039	Spain		PRODUCT NAME: PIBRENTASVIR O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/17/1213; DATE OF AUTHORISATION: 20170726; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1213; DATE OF FIRST AUTHORISATION IN EEA: 20170726

Market Dynamics and Financial Trajectory for Viekira XR: An In-Depth Analysis

Last updated: July 27, 2025

---

Introduction

Viekira XR (ombitasvir, paritaprevir co-packaged with ritonavir, dasabuvir) represents a significant pharmacological advancement in the treatment of chronic hepatitis C virus (HCV) infection. Since its approval in 2015 by the U.S. Food and Drug Administration (FDA), Viekira XR has navigated a complex landscape characterized by evolving treatment paradigms, competitive pressures, and shifting market dynamics. This analysis explores the factors shaping its commercial trajectory, examines the competitive environment, and evaluates the financial outlook for this oral antiviral combination.

---

Market Landscape for Hepatitis C Treatment

The global hepatitis C market has undergone transformative shifts, driven by the advent and rapid adoption of direct-acting antivirals (DAAs). Prior to 2014, interferon-based therapies yielded low cure rates and high adverse event profiles. The advent of DAAs, including Viekira XR, revolutionized the therapeutic landscape, offering high sustained virologic response (SVR) rates, shortened treatment durations, and improved tolerability [[1]].

Market Size & Growth Trajectory

In 2022, the global hepatitis C therapeutics market was valued at approximately $12 billion, with a compound annual growth rate (CAGR) of about 4% over the previous five years [[2]]. The increasing adoption of pan-genotypic regimens, coupled with WHO elimination targets, supports ongoing market expansion. However, growth is tempered by the declining prevalence of diagnosed HCV infections, particularly in developed markets, due to widespread screening and treatment.

---

Positioning of Viekira XR in the Market

Viekira XR, as part of AbbVie's portfolio, encountered competition from other regimens, notably Harvoni (ledipasvir/sofosbuvir) by Gilead Sciences and Epclusa (sofosbuvir/velpatasvir). Its distinct formulation—extended-release tablets—aimed to optimize patient adherence and simplify dosing.

Clinical Efficacy & Safety Profile

Viekira XR demonstrated high SVR rates across multiple genotypes, especially in genotype 1, which historically represented the most common and challenging HCV subtype. Its controlled-release formulation improved tolerability compared to the original Viekira Pak, leading to improved patient compliance [[3]].

Market Penetration & Adoption Factors

Despite its efficacy, Viekira XR faced competition primarily driven by:

• Broad-spectrum pan-genotypic options: Epclusa offers efficacy across all genotypes, reducing the need for genotype-specific regimens.
• Price competition: Gilead's offerings have been aggressively priced, supported by established payer relationships.
• Healthcare provider preferences: Physicians tend to favor regimens with the broadest efficacy and safety profiles, contributing to Viekira XR's relatively limited market share.

---

Market Dynamics Impacting Viekira XR

1. Competitive Landscape Evolution

The competitive environment shifted with the introduction of newer, pan-genotypic agents. Gilead's Harvoni and Epclusa, with their high efficacy and simplified dosing, secured substantial market share early on. AbbVie's Viekira XR struggled to displace these regimens, especially given the lack of a pan-genotypic claim initially. However, subsequent formulations and combinations sought to address these gaps.

2. Patent Expirations & Generic Entry

While Viekira XR benefits from patent protection until the late 2020s, impending patent cliffs threaten future revenue streams. The possibility of generic entry in emerging markets could significantly erode its market share, especially in low- and middle-income countries where affordability is critical.

3. Pricing & Reimbursement Policies

Pricing strategies significantly impact Viekira XR's market performance. In highly regulated markets like the U.S., payer negotiations, formulary placements, and prior authorization requirements influence prescribing patterns. AbbVie's ability to negotiate favorable reimbursement terms determines access and uptake.

4. Regulatory and Labeling Changes

Registration of combination regimens with expanded indications has fostered competition. The inclusion of weight-based or genotype-agnostic indications improves a drug’s market appeal but increases competition pressure, especially from newer agents with broader claims.

5. Market Penetration in Developing Regions

While developed markets see stagnant or declining HCV prevalence, emerging markets exhibit growth opportunities. However, affordability barriers and local regulatory hurdles limit Viekira XR's penetration in these regions.

---

Financial Trajectory and Revenue Projections

Historical Revenue Performance

AbbVie's HCV franchise, which included Viekira XR, peaked during 2015-2017, driven by high demand upon initial approval. However, revenue declined thereafter, reflecting market saturation and increased competition [[4]].

Projected Trends

• Short-term (2023–2025): The revenue contribution of Viekira XR is expected to stabilize, supported by existing patient populations. However, new patient initiation declines as highly effective pan-genotypic regimens dominate.
• Medium to Long-term (2026–2030): Patent expiration and possible generic entry will compress prices. Revenue from Viekira XR and similar regimens will likely decline, unless new indications or formulations emerge.

Key Revenue Drivers

• Market Penetration in Emerging Markets: Opportunities exist, especially if priced competitively.
• Combination License Expansion: Incorporation into combination therapies may extend its lifecycle.
• Clinical Advantage Development: Demonstrating superior efficacy or safety could reclaim market share.

Potential Growth Catalysts

• Development of next-generation formulations with improved dosing convenience.
• Strategic collaborations or licensing agreements in underserved markets.
• Expanded indications for special populations.

---

Strategic Considerations for Stakeholders

Pharmaceutical Companies

To mitigate revenue decline, companies should innovate formulations, pursue new indications, and collaborate within treatment guidelines focusing on personalized medicine.

Healthcare Payers

Negotiating value-based pricing and emphasizing cost-effectiveness models would optimize resource allocation and maintain access to effective regimens.

Investors

Monitoring patent statuses, pipeline developments, and emerging competition is vital for making informed investment decisions.

---

Conclusion

Viekira XR's trajectory exemplifies the challenges of sustaining market relevance in the rapidly evolving hepatitis C landscape. While initial uptake was robust, subsequent competition, market saturation, and pricing pressures have curtailed growth. Its future depends heavily on strategic repositioning, potential pipeline advancements, and market expansion efforts.

---

Key Takeaways

• Market Saturation Limits Growth: High cure rates and widespread adoption have led to market saturation, constraining Viekira XR’s revenue growth potential.
• Competitive Landscape Is Intense: Gilead’s pan-genotypic regimens and generics threaten Viekira XR’s future market share.
• Patent and Pricing Dynamics Are Critical: Patent expirations combined with pricing strategies significantly influence long-term financial viability.
• Opportunities Exist in Emerging Markets: Tailored strategies could unlock growth in lower-income regions, especially with affordable pricing.
• Innovation Is Essential: Next-generation formulations or expanded indications could prolong product relevance amid fierce competition.

---

FAQs

1. What are the key differentiators of Viekira XR compared to other hepatitis C therapies?
Viekira XR offers a controlled-release formulation with a simplified, once-daily dosing schedule, which enhances patient adherence. However, its initial genotype-specific efficacy and lack of pan-genotypic coverage limit its competitive edge over newer regimens.

2. How has the competition from Gilead's pan-genotypic drugs affected Viekira XR's market share?
The broader efficacy and simplified regimens of Gilead’s Harvoni and Epclusa have overshadowed Viekira XR, leading to decreased prescriptions, particularly in markets prioritizing broad-spectrum therapies.

3. Is Viekira XR still a viable treatment option in the current hepatitis C market?
Yes, particularly in specific patient populations or regions where cost considerations or prior treatment failures make it a suitable choice. Still, its use is increasingly limited in favor of pan-genotypic options with broader coverage and possibly better reimbursement terms.

4. What potential strategies can extend the product lifecycle of Viekira XR?
Strategies include developing combination therapies with new agents, expanding indications, optimizing formulations, and targeting markets with limited access to newer drugs.

5. When might patent expiration significantly impact Viekira XR’s revenue?
Patent protections are expected to last until at least 2027–2029, but imminent biosimilar or generic entrants in certain markets could accelerate revenue erosion in the next 3–5 years, especially outside of patent-protected regions.

---

References

[1] World Health Organization. "Global Hepatitis Report 2017."
[2] Market Research Future. "Hepatitis C Therapeutics Market Analysis and Forecast," 2022.
[3] FDA. "Viekira XR (ombitasvir, paritaprevir, and dasabuvir) prescribing information," 2015.
[4] AbbVie Financial Reports, 2015–2022.